Larad has a number of vaccines in development to address viral diseases in poultry and aquaculture: two high growth segments of food animal production with increasingly complex disease challenges.
Our goal is to create virus-like-particle (VLP) and subunit vaccines that are readily adaptable to the evolving disease challenges and have added advantages in safety, stability, production, and administration. As a B2B firm, we provide vaccine manufacturers with innovative, cost-effective solutions for rapid market scale-up.
We have several technologies available for out-licensing and are excited to pursue strategic development projects for additional viruses. To collaborate with us, please call (330)201-4485 or send us an email.
IBDV is a contagious immunosuppressive disease affecting nearly all poultry-producing regions of the world. Control is best achieved by vaccination of breeder flocks to produce maternal immunity in the chicks, but frequent genetic mutations, reassorting of genome segments, and genetic recombination can increase virulence and alter antigenicity, rendering commercial vaccines ineffective. Larad’s IBDV-VLP vaccine provides an unparalleled advantage in breeder vaccination because it can be updated to address specific viral strains.
ARV infections are sources of arthritis/tenosynovitis, malabsorption syndrome, stunting/runting, enteric disease, immunosuppression, and respiratory disease in poultry. U.S. poultry experience a continued challenge as a result of variant reoviruses that emerged in 2012. Commercial vaccines alone are no longer enough to provide adequate protection, so autogenous vaccines are a necessary supplement. Larad's reovirus vaccines use VLP and subunit protein technologies. The customizability offered provides a significant advantage over the traditional vaccines and can save valuable time in managing the virus compared to autogenous vaccines.
CAV causes anemia, decreased weight gain, transient immunosuppression, and increased mortality in young chickens. Older chickens are subjected to subclinical infections, leaving flocks vulnerable to secondary infections that have costly economic impacts. Live-attenuated CAV vaccines are the only vaccine solutions available; due to virus instability, inactivated vaccines have historically been unsuccessful. Larad’s CAV-VLP vaccine using non-replicating, concentrated viral proteins will provide a unique market solution to aid disease management.
Infectious bronchitis is a highly contagious virus in chickens that contributes to upper respiratory tract disease, decreased egg production, and nephritis. During outbreaks, farm-level losses can be up to $3,500 per 1,000 birds. Vaccination is important in the management of the disease, but the live-attenuated and killed vaccines fall short. Although protective, their efficacy wanes over time as IBV mutates. Larad’s subunit IBV vaccine in development aims to address this issue by offering a custom solution that also has advantages in vaccine production.
IPNV is a severe disease of salmonid fish that can cause up to 90% mortality and persists as a subclinical infection. It is highly contagious and found worldwide, making eradication difficult. Control of IPNV is generally well-managed using commercial vaccines and "QTL fish" that are bred with resistance to the virus. However, recent outbreaks indicate the re-emergence of IPNV, resulting in millions of dollars of annual losses. Larad’s IPNV-VLP vaccine can be tailor-made to address these emerging challenges quickly and effectively.
~ Custom vaccines keeping pace with mutating viruses ~